Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults

Chang, Anne B., Lasserson, Toby J., Gaffney, Justin, Connor, Frances L. and Garske, Luke A. (2009) Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults. Cochrane Database of Systematic Reviews, 4: CD004823.1-CD004823.53. doi:10.1002/14651858.CD004823.pub3


Author Chang, Anne B.
Lasserson, Toby J.
Gaffney, Justin
Connor, Frances L.
Garske, Luke A.
Title Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults
Journal name Cochrane Database of Systematic Reviews   Check publisher's open access policy
ISSN 1469-493X
Publication date 2009
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1002/14651858.CD004823.pub3
Issue 4
Start page CD004823.1
End page CD004823.53
Total pages 53
Place of publication Oxford, United Kingdom
Publisher John Wiley & Sons
Language eng
Formatted abstract
Background: Gastroesophageal reflux disease (GORD) is said to be the causative factor in up to 41% of adults with chronic cough. However cough and GORD are common ailments and their co-existence by chance is high. Also cough can induce reflux episodes. Treatment for GORD includes conservative measures (diet manipulation), pharmaceutical therapy (motility or prokinetic agents, H2-antagonist and proton pump inhibitors (PPI)) and fundoplication.
Objectives: To evaluate the efficacy of GORD treatment on chronic cough in children and adults with GORD and prolonged cough that is not related to an underlying respiratory disease i.e. non-specific chronic cough.
Search strategy: We searched the Cochrane Register of Controlled Trials (CENTRAL), the Cochrane Airways Group Specialised Register, MEDLINE and EMBASE databases, review articles and reference lists of relevant articles. The date of last search was 24th April 2009.
Selection criteria: All randomised controlled trials (RCTs) on GORD treatment for cough in children and adults without primary lung disease.
Data collection and analysis: Two review authors independently assessed trial quality and extracted. Study authors were contacted for further information.
Main results: Eighteen studies (5 paediatric, 13 adults) were included. None of the paediatric studies could be included in meta-analysis. In adults, analysis on use of H2 antagonist, motility agents and conservative treatment for GORD were not possible (from lack of data) and there were no controlled studies on fundoplication as an intervention. Nine adult studies comparing PPI (two to three months) to placebo were analysed for various outcomes in the meta-analysis. Enrolment of participants subjects for two studies were primarily from medical clinics and another eight studies were otolaryngology clinic patients or patients with laryngeal symptoms. Using "intention to treat", pooled data from studies resulted in no significant difference between treatment and placebo in total resolution of cough, Odds Ratio 0.46 (95% confidence interval (CI) 0.19 to 1.15). Pooled data revealed no overall significant improvement in cough outcomes (end of trial or change in cough scores). Significant differences were only found in sensitivity analyses. A significant improvement in change of cough scores was found in end of intervention (two to three months) in those receiving PPI with a standardised mean difference of -0.41 (95% CI -0.75 to -0.07) using generic inverse variance analysis on cross over trials. Two studies reported improvement in cough after five days to two weeks of treatment.
Authors' conclusions: There is insufficient evidence to definitely conclude that GORD treatment with PPI is universally beneficial for cough associated with GORD in adults. The beneficial effect was only seen in sub-analysis. The optimal duration of such a trial of therapy to evaluate response could not be ascertained although two RCTs reported significant change by 2-weeks of therapy. Clinicians should be cognisant of a period (natural resolution with time) and placebo effect in studies that utilise cough as an outcome measure. Future paediatric and adult studies should be double blind, randomised controlled, parallel design, using treatments for at least two months, with validated subjective and objective cough outcomes and include ascertainment of time to respond as well as assessment of acid and/or non-acid reflux.
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ
Additional Notes Article # CD004823

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: ERA 2012 Admin Only
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 21 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 39 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Mon, 19 Dec 2011, 15:40:32 EST by Jane Medhurst on behalf of Child Health Research Centre